ARCHIVES

IDMC Recommends Halting Phase III Trial Of Onartuzumab in MET-Positive NSCLC

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

Amgen Claimed QOL Benefit Despite FDA Label Change.

May 18, 2007

Tough Year Seen for Cooperative Groups; Priority Payment Questioned

December 2, 1988

In Congress: Senate Passes Bill For DOD Medical Research Funding

August 14, 1998

First Round Of Cooperative Group Mergers Falls Short Of NCI’s Stated Goal

February 4, 2011

In Brief: Clearinghouse Charter Renewed For Two Years; Good On China, Carbone On Communciation

May 26, 1978

In Brief: David Cole Named President of The Medical University of South Carolina

May 9, 2014